JAMIE BREWER: Open Payments
NPI 1154733392 · FLORENCE, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,276 in 110 payments from 24 companies in 2025. Trend: 2023 $1,419 · 2024 $1,682 · 2025 $2,276
Food & beverage: $2,276
| Company | Payments | Amount |
|---|---|---|
| Dexcom, Inc. | 8 | $271 |
| Corcept Therapeutics | 18 | $271 |
| Bayer Healthcare Pharmaceuticals Inc. | 10 | $218 |
| Novo Nordisk Inc | 13 | $217 |
| Astellas Pharma US Inc | 5 | $193 |
| Lilly USA, LLC | 10 | $178 |
| Tandem Diabetes Care, Inc. | 9 | $128 |
| Xeris Pharmaceuticals, Inc. | 5 | $114 |
| RGH Enterprises LLC | 1 | $93 |
| Esperion Therapeutics, Inc. | 5 | $78 |
Products named: Dexcom G6 Transmitter, Korlym, Kerendia, Veozah, MOUNJARO, t:slim X2 Insulin Pump with Control-IQ, RECORLEV, NEXLETOL.
Industry payments across MS — which companies pay providers there.
